Physicians’ Education Resource
Last Modified: May 20, 2010
Conference Dates: September 24-25, 2010
Conference Location: United States
Sponsoring Group: Physicians’ Education Resource
Conference Web Page URL: www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/560
Topics Covered: At the conclusion of this symposium, you should be able to: Implement appropriate risk stratification measures and monitoring plans for patients with newly diagnosed myeloma, lymphoma, and leukemia Discuss current treatment options for patients with newly diagnosed or relapsed/refractory myeloma, lymphoma, and leukemia Assess the clinical utility of emerging novel agents for the treatment of patients with myeloma, lymphoma, and leukemia Evaluate the role of hematopoietic stem cell transplantation for eligible patients with hematologic malignancies.
Conference Objectives: Designed to address gaps in knowledge for practicing medical oncologists and hematologists and will present current standards, practical issues, and controversies in the management of myeloma, lymphoma, and leukemia, and other hematologic malignancies. In addition, controversies in the management of these diseases will be discussed in the form of didactic lectures with panel discussions and case-based discussions with interactive response system capabilities.
Who Should Attend: medical oncologists and hematologists, Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies are also invited to attend.
Conference Agenda: This activity is presented by Physicians’ Education Resource in conjunction with the University of Southern California. *Please see our website for Agenda.
Conference Fees: Please see our website for current pricing
Continuing Education: No
Nov 4, 2011 - Use of zidovudine and interferon alfa with chemotherapy (combined first-line therapy) prolongs survival in patients with adult T-cell leukemia/lymphoma, according to a study published online Oct. 31 in the Journal of Clinical Oncology.